| # | Drug | Count |
|---|---|---|
| 0 | OXALIPLATIN | 61 |
| 1 | BEVACIZUMAB | 58 |
| 2 | FLUOROURACIL | 53 |
| 3 | FLUOROURACIL CREAM, 0.5% | 53 |
| 4 | PANITUMUMAB | 44 |
| 5 | CAPECITABINE | 34 |
| 6 | ADALIMUMAB | 25 |
| 7 | INFLIXIMAB | 22 |
| 8 | REGORAFENIB | 22 |
| 9 | AZATHIOPRINE | 20 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | BEVACIZUMAB-ADCD | 1 | 0.0049 |
| 1 | PANITUMUMAB | 44 | 0.0027 |
| 2 | SOTORASIB | 7 | 0.0020 |
| 3 | REGORAFENIB | 22 | 0.0019 |
| 4 | FRUQUINTINIB | 7 | 0.0018 |
| 5 | PROCHLORPERAZINE EDISYLATE | 2 | 0.0017 |
| 6 | TRIFLURIDINE AND TIPIRACIL | 16 | 0.0015 |
| 7 | BEVACIZUMAB-AWWB | 6 | 0.0013 |
| 8 | DORAVIRINE | 1 | 0.0013 |
| 9 | BISACODYL 5MG | 1 | 0.0011 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Epidermal Growth Factor Receptor Antagonist [EPC] | 52 | 0.0011 |
| 1 | Phenothiazine [EPC] | 12 | 0.0004 |
| 2 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 65 | 0.0004 |
| 3 | Nucleoside Metabolic Inhibitor [EPC] | 96 | 0.0004 |
| 4 | Calcitonin [EPC] | 1 | 0.0003 |
| 5 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 2 | 0.0003 |
| 6 | Platinum-based Drug [EPC] | 63 | 0.0002 |
| 7 | Nucleoside Analog Antiviral [EPC] | 19 | 0.0002 |
| 8 | Purine Antimetabolite [EPC] | 20 | 0.0002 |
| 9 | Catechol-O-Methyltransferase Inhibitor [EPC] | 1 | 0.0002 |